1. Home
  2. GPCR vs HDL Comparison

GPCR vs HDL Comparison

Compare GPCR & HDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GPCR
  • HDL
  • Stock Information
  • Founded
  • GPCR 2016
  • HDL 2016
  • Country
  • GPCR United States
  • HDL Singapore
  • Employees
  • GPCR N/A
  • HDL N/A
  • Industry
  • GPCR
  • HDL Restaurants
  • Sector
  • GPCR
  • HDL Consumer Discretionary
  • Exchange
  • GPCR Nasdaq
  • HDL Nasdaq
  • Market Cap
  • GPCR 1.6B
  • HDL 1.4B
  • IPO Year
  • GPCR 2023
  • HDL 2024
  • Fundamental
  • Price
  • GPCR $27.06
  • HDL $23.21
  • Analyst Decision
  • GPCR Strong Buy
  • HDL
  • Analyst Count
  • GPCR 7
  • HDL 0
  • Target Price
  • GPCR $81.29
  • HDL N/A
  • AVG Volume (30 Days)
  • GPCR 1.0M
  • HDL 16.5K
  • Earning Date
  • GPCR 03-07-2025
  • HDL 02-20-2025
  • Dividend Yield
  • GPCR N/A
  • HDL N/A
  • EPS Growth
  • GPCR N/A
  • HDL N/A
  • EPS
  • GPCR N/A
  • HDL 0.09
  • Revenue
  • GPCR N/A
  • HDL $759,894,000.00
  • Revenue This Year
  • GPCR N/A
  • HDL $18.96
  • Revenue Next Year
  • GPCR N/A
  • HDL $14.25
  • P/E Ratio
  • GPCR N/A
  • HDL $258.52
  • Revenue Growth
  • GPCR N/A
  • HDL 16.09
  • 52 Week Low
  • GPCR $23.50
  • HDL $13.94
  • 52 Week High
  • GPCR $62.74
  • HDL $30.00
  • Technical
  • Relative Strength Index (RSI)
  • GPCR 42.52
  • HDL N/A
  • Support Level
  • GPCR $23.50
  • HDL N/A
  • Resistance Level
  • GPCR $27.68
  • HDL N/A
  • Average True Range (ATR)
  • GPCR 1.71
  • HDL 0.00
  • MACD
  • GPCR 0.20
  • HDL 0.00
  • Stochastic Oscillator
  • GPCR 51.30
  • HDL 0.00

About GPCR Structure Therapeutics Inc.

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.

About HDL SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares

Super Hi International Holding Ltd is an investment holding company and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan.

Share on Social Networks: